相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
Feng Wang et al.
MABS (2020)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
Cesar Rodriguez et al.
BLOOD (2020)
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Simon J. Harrison et al.
BLOOD (2020)
Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Alexander M. Lesokhin et al.
BLOOD (2020)
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall et al.
BLOOD (2020)
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Dawn Swan et al.
HEMASPHERE (2020)
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works et al.
MOLECULAR CANCER THERAPEUTICS (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
Bone marrow transplantation generates T cell-dependent control of myeloma in mice
Slavica Vuckovic et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model
Camille Guillerey et al.
JCI INSIGHT (2019)
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E. Matyskiela et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
Kyohei Nakamura et al.
CANCER CELL (2018)
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Yawara Kawano et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Emma C. Fink et al.
BLOOD (2018)
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns
Nicole J. Gormley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
Arianna Calcinotto et al.
NATURE COMMUNICATIONS (2018)
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma
Xiuli Wang et al.
CLINICAL CANCER RESEARCH (2018)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma
Rachel E. Cooke et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Marta Chesi et al.
NATURE MEDICINE (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Asymmetric PI3K Signaling Driving Developmental and Regenerative Cell Fate Bifurcation
Wen-Hsuan W. Lin et al.
CELL REPORTS (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P. Chamberlain et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Lenalidomide induces degradation of IKZF1 and IKZF3
Jan Kroenke et al.
ONCOIMMUNOLOGY (2014)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells
Kevin Man et al.
NATURE IMMUNOLOGY (2013)
Behavioral characterization of cereblon forebrain-specific conditional null mice: A model for human non-syndromic intellectual disability
Anjali M. Rajadhyaksha et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi et al.
BLOOD (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1
Xinyuan Zhou et al.
IMMUNITY (2010)
Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory
Gregoire Jeannet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Luca Gattinoni et al.
NATURE MEDICINE (2009)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses
KE Foulds et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
